Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $3.58 USD
Change Today +0.26 / 7.83%
Volume 9.5M
As of 4:00 PM 05/28/15 All times are local (Market data is delayed by at least 15 minutes).

xoma corp (XOMA) Snapshot

Previous Close
Day High
Day Low
52 Week High
11/28/14 - $5.95
52 Week Low
04/30/15 - $2.92
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for XOMA CORP (XOMA)

xoma corp (XOMA) Related Bloomberg News

View More Bloomberg News

xoma corp (XOMA) Related Businessweek News

No Related Businessweek News Found

xoma corp (XOMA) Details

XOMA Corporation discovers and develops antibody-based therapeutics in the United States, Europe, and the Asia Pacific. The company’s lead product candidate includes gevokizumab, a proprietary humanized allosteric-modulating monoclonal antibody that binds to the inflammatory cytokine interleukin-1 beta, which is in Phase III clinical trial for NIU and Behçet’s disease uveitis, pyoderma gangrenosum, active non-infectious anterior scleritis, autoimmune inner ear disease, and cardiovascular diseases, as well as diseases under the neutrophilic dermatoses designation, Schnitzler syndrome, and other diseases; and various proof-of-concept studies comprising polymyositis/dermatomyositis, Schnitzler syndrome, and giant cell arteritis. Its proprietary product pipeline also comprises XOMA metabolic activating, sensitizing, and deactivating/antagonizing antibodies that are in preclinical stage for the treatment of diabetes patients; XOMA 3AB, a multi-antibody product for the treatment of human botulism poisoning; and XOMA 629, a topical anti-bacterial product for the treatment of human immune system. In addition, the company licenses antibody discovery, optimization, and development technologies, including Antibody Discovery Advanced Platform Technologies, ModulX, and OptimX. It has collaboration and licensing agreements with Les Laboratoires Servier; National Institute of Allergy and Infectious Diseases; Takeda Pharmaceutical Company Limited; Novartis AG; Pfizer Inc.; Symplmed Pharmaceuticals, LLC; and Texas A&M University. The company was founded in 1981 and is headquartered in Berkeley, California.

181 Employees
Last Reported Date: 05/7/15
Founded in 1981

xoma corp (XOMA) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $569.5K
Founder, Chief Scientific Officer, Executive ...
Total Annual Compensation: $250.3K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $411.0K
Chief Commercial Officer and Vice President
Total Annual Compensation: $391.4K
Compensation as of Fiscal Year 2014.

xoma corp (XOMA) Key Developments

XOMA Corporation Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015; Provides Capital Expenditures Guidance for 2015

XOMA Corporation reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. The company recorded total revenues of $2.7 million compared with $3.4 million during the corresponding period of 2014. The decrease in the first quarter 2015 Revenue was due primarily to the receipt of a $0.5 million milestone payment related to an out-licensing arrangement received in the first quarter of 2014. Loss from operations was $22.6 million against $23.5 million last year. XOMA had net loss of $21.7 million or $0.19 per basic and diluted share compared with net loss of $4.7 million or $0.21 per diluted share in the quarter ended March 31, 2014. The net losses in the three months ended March 31, 2015 and 2014, included a $40,000 loss and $20.0 million gain, respectively, in non-cash revaluations of contingent warrant liabilities, resulting primarily from fluctuations in XOMA's stock price. Excluding those revaluations, the net loss for the three months ended March 31, 2015 was $21.7 million compared with net loss of $24.7 million for the same reporting period in 2014. The company expects to spend approximately $60 million to $65 million in cash for ongoing operating activities during 2015. The company's principal expenditures are costs associated with its gevokizumab Phase 3 clinical programs. The guidance assumes license and contract-related revenue to be received during the course of the year.

XOMA Corporation to Report Q1, 2015 Results on May 07, 2015

XOMA Corporation announced that they will report Q1, 2015 results on May 07, 2015

XOMA Corporation, Q1 2015 Earnings Call, May 07, 2015

XOMA Corporation, Q1 2015 Earnings Call, May 07, 2015


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
XOMA:US $3.58 USD +0.26

XOMA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
arGEN-X BV €10.44 EUR -0.01
BioInvent International AB kr2.32 SEK +0.05
Intrexon Corp $40.88 USD -0.27
MorphoSys AG €68.70 EUR +0.80
PDL BioPharma Inc $6.80 USD +0.08
View Industry Companies

Industry Analysis


Industry Average

Valuation XOMA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 21.6x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 15.5x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact XOMA CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at